Vanguard Group
FENC icon

Vanguard Group’s Fennec Pharmaceuticals FENC Stock Holding History

Vanguard Group’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$8.22M Buy
1,067,651
+111,887
+12% +$919K ﹤0.01% 3064
2025
Q3 		$8.95M Sell
955,764
-11,328
-1% -$98.1K ﹤0.01% 3034
2025
Q2 		$8.03M Buy
967,092
+2,472
+0.3% +$16.9K ﹤0.01% 3023
2025
Q1 		$5.87M Sell
964,620
-5,134
-0.5% -$33K ﹤0.01% 3109
2024
Q4 		$6.13M Sell
969,754
-78,137
-7% -$400K ﹤0.01% 3182
2024
Q3 		$5.24M Buy
1,047,891
+21,237
+2% +$123K ﹤0.01% 3261
2024
Q2 		$6.27M Buy
1,026,654
+13,028
+1% +$108K ﹤0.01% 3154
2024
Q1 		$11.3M Sell
1,013,626
-126,437
-11% -$1.27M ﹤0.01% 2892
2023
Q4 		$12.8M Buy
1,140,063
+1,058,295
+1,294% +$8.77M ﹤0.01% 2810
2023
Q3 		$614K Buy
81,768
+1,895
+2% +$15.4K ﹤0.01% 3997
2023
Q2 		$705K Buy
+79,873
New +$664K ﹤0.01% 4012
2021
Q2 		– Sell
-111,372
Closed -$692K – 4439
2021
Q1 		$692K Buy
111,372
+13,864
+14% +$104K ﹤0.01% 4076
2020
Q4 		$727K Buy
97,508
+12,338
+14% +$94K ﹤0.01% 3896
2020
Q3 		$516K Sell
85,170
-5,094
-6% -$35.9K ﹤0.01% 3806
2020
Q2 		$754K Buy
+90,264
New +$671K ﹤0.01% 3679
2019
Q2 		– Sell
-45,067
Closed -$219K – 4174
2019
Q1 		$219K Buy
45,067
+3,458
+8% +$22.7K ﹤0.01% 3906
2018
Q4 		$266K Sell
41,609
-1,879
-4% -$13.1K ﹤0.01% 3845
2018
Q3 		$357K Buy
43,488
+2,868
+7% +$26.6K ﹤0.01% 3906
2018
Q2 		$424K Buy
+40,620
New +$482K ﹤0.01% 3848

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return

Vanguard Group's FENC Position: Q4 2025 in Review

Vanguard Group increased its Fennec Pharmaceuticals (FENC) stake by 12% in Q4 2025, buying an estimated $919K and bringing the position to 1,067,651 shares worth $8.22M. The position accounts for ﹤0.01% of the portfolio, ranked #3064.

Vanguard Group first reported a position in FENC in Q2 2018 and has held it in 19 quarters since. The position peaked at $12.8M in Q4 2023. 96 funds tracked by Wall St. Rank hold FENC as of Q4 2025.

  • Vanguard Group held 1,067,651 shares of Fennec Pharmaceuticals worth $8.22M as of Q4 2025.
  • Vanguard Group bought 111,887 Fennec Pharmaceuticals shares in Q4 2025, an estimated $919K.
  • Fennec Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3064 holding.
  • Vanguard Group first reported a position in Fennec Pharmaceuticals in Q2 2018 and has held it in 19 quarters since.
  • Vanguard Group's Fennec Pharmaceuticals position peaked at $12.8M in Q4 2023.
  • 96 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.